{"id":52006,"date":"2022-12-14T23:02:18","date_gmt":"2022-12-14T22:02:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/"},"modified":"2022-12-14T23:02:18","modified_gmt":"2022-12-14T22:02:18","slug":"zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/","title":{"rendered":"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium"},"content":{"rendered":"
\n

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, 2023.\n<\/p>\n

<\/a><\/p>\n

\nThe GEA cohort of this Phase 2 clinical trial (NCT03929666<\/a>) was fully recruited as of March 1, 2022 with clinical trial sites in the United States, Canada, Chile and South Korea. Enrollment into the biliary tract cancer and colorectal cancer cohorts of the trial continues. The Phase 2 data in GEA supports zanidatamab development in the Phase 3 HERIZON-GEA-01 study, evaluating zanidatamab in combination with chemotherapy with or without tislelizumab for the first-line treatment of HER2-positive GEA (NCT05152147<\/a>).\n<\/p>\n

\nThe poster presentation will be available on Thursday, January 19, 2023 on the conference website<\/a> as well as the Zymeworks website<\/a>.\n<\/p>\n

\nTitle: Zanidatamab + chemotherapy as first-line treatment for HER2-expressing metastatic gastroesophageal adenocarcinoma (mGEA)
\n
Lead Author: Elena Elimova, MD, MSc, Princess Margaret Cancer Center, Toronto, Canada
\n
Abstract: 347
\n
Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers\n<\/p>\n

\nAbout Zanidatamab<\/b>\n<\/p>\n

\nZanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric\u2122 platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade, increased binding and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2 and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks has entered into separate agreements with each of BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz), granting each of BeiGene and Jazz with exclusive rights to develop and commercial zanidatamab throughout various counties around world.\n<\/p>\n

\nAbout Zymeworks Inc.<\/b>\n<\/p>\n

\nZymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks\u2019 suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks\u2019 lead clinical candidate, zanidatamab, is a novel Azymetric\u2122 HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks\u2019 second clinical candidate, zanidatamab zovodotin (ZW49), is a novel bispecific HER2 \u2011targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks\u2019 proprietary ZymeLink\u2122 linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com<\/a>. For additional information about Zymeworks, visit www.zymeworks.com<\/a> and follow @ZymeworksInc<\/a> on Twitter.\n<\/p>\n

\nCautionary Note Regarding Forward-Looking Statements<\/b>\n<\/p>\n

\nThis press release includes \u201cforward-looking statements\u201d or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, but are not limited to, statements that relate to the potential therapeutic effects of zanidatamab and Zymeworks\u2019 other product candidates; Zymeworks\u2019 clinical development of its product candidates and enrollment in its clinical trials; anticipated clinical data presentations; the commercial potential of technology platforms and product candidates; the ability to advance product candidates into later stages of development; and other information that is not historical information. When used herein, words such as \u201cplan\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cmay\u201d, \u201canticipate\u201d, \u201cpotential\u201d, \u201cwill\u201d, \u201ccontinues\u201d, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks\u2019 current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation: future clinical trials may not demonstrate safety and efficacy of any of Zymeworks\u2019 or its collaborators\u2019 product candidates; clinical trials may not demonstrate safety and efficacy of any of Zymeworks\u2019 or its collaborators\u2019 product candidates; any of Zymeworks\u2019 or its partners\u2019 product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; the impact of the COVID-19 pandemic on Zymeworks\u2019 business, research and clinical development plans and timelines and results of operations, including impact on its clinical trial sites, collaborators, and contractors who act for or on Zymeworks\u2019 behalf, may be more severe and more prolonged than currently anticipated; the impact of new or changing laws and regulations; market conditions; inability to maintain or enter into new partnerships or strategic collaborations; and the factors described under \u201cRisk Factors\u201d in Zymeworks\u2019 quarterly and annual reports filed with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for its quarter ended September 30, 2022 (a copy of which may be obtained at www.sec.gov<\/a> and www.sedar.com<\/a>).\n<\/p>\n

\nAlthough Zymeworks believes that such forward-looking statements are reasonable, there can be no assurance they will prove to be correct. Investors should not place undue reliance on forward-looking statements. The above assumptions, risks and uncertainties are not exhaustive. Forward-looking statements are made as of the date hereof and, except as may be required by law, Zymeworks undertakes no obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances, or to reflect the occurrences of unanticipated events.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor inquiries:<\/b>
Jack Spinks
\n
(604) 678-1388
\n
ir@zymeworks.com<\/a>\n<\/p>\n

\nMedia inquiries:<\/b>
Diana Papove
\n
(604) 678-1388
\n
media@zymeworks.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52006","6":"format-standard","7":"category-industry"},"yoast_head":"\nZanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-14T22:02:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221214005989\/en\/183056\/21\/Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium\",\"datePublished\":\"2022-12-14T22:02:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/\"},\"wordCount\":1029,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005989\\\/en\\\/183056\\\/21\\\/Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/\",\"name\":\"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005989\\\/en\\\/183056\\\/21\\\/Logo.jpg\",\"datePublished\":\"2022-12-14T22:02:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005989\\\/en\\\/183056\\\/21\\\/Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221214005989\\\/en\\\/183056\\\/21\\\/Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/","og_locale":"en_US","og_type":"article","og_title":"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Pharma Trend","og_description":"VANCOUVER, British Columbia–(BUSINESS WIRE)–Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the upcoming presentation of mature Phase 2 data evaluating zanidatamab in combination with chemotherapy as first-line treatment for HER2-positive gastroesophageal adenocarcinoma (GEA) at the ASCO Gastrointestinal Cancers Symposium, taking place in San Francisco, CA and virtually on January 19-21, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/","og_site_name":"Pharma Trend","article_published_time":"2022-12-14T22:02:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221214005989\/en\/183056\/21\/Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium","datePublished":"2022-12-14T22:02:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/"},"wordCount":1029,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221214005989\/en\/183056\/21\/Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/","url":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/","name":"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221214005989\/en\/183056\/21\/Logo.jpg","datePublished":"2022-12-14T22:02:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221214005989\/en\/183056\/21\/Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221214005989\/en\/183056\/21\/Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/zanidatamab-clinical-data-selected-for-presentation-at-the-american-society-of-clinical-oncology-asco-gastrointestinal-cancers-symposium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Zanidatamab Clinical Data Selected For Presentation At The American Society Of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52006","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52006"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52006\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52006"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52006"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52006"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}